These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 8288424)

  • 1. Disability Weights for Osteoporosis and Osteoporotic Fractures in South Korea.
    Bae G; Kim E; Kwon HY; An J; Park J; Yang H
    J Bone Metab; 2019 May; 26(2):83-88. PubMed ID: 31223604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews.
    Finch AP; Brazier JE; Mukuria C
    Eur J Health Econ; 2018 May; 19(4):557-570. PubMed ID: 28560520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-value analysis of health interventions: introduction and update on methods and preference data.
    Nord E
    Pharmacoeconomics; 2015 Feb; 33(2):89-95. PubMed ID: 25488879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming EQ-5D utilities for use in cost–value analysis of health programs.
    Nord E; Johansen R
    Eur J Health Econ; 2015 Apr; 16(3):313-28. PubMed ID: 24659019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theory of constraints for publicly funded health systems.
    Sadat S; Carter MW; Golden B
    Health Care Manag Sci; 2013 Mar; 16(1):62-74. PubMed ID: 22907662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity as an independent determinant of the social value of a health service.
    Richardson JR; McKie J; Peacock SJ; Iezzi A
    Eur J Health Econ; 2011 Apr; 12(2):163-74. PubMed ID: 20455072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trading people versus trading time: what is the difference?
    Damschroder LJ; Roberts TR; Goldstein CC; Miklosovic ME; Ubel PA
    Popul Health Metr; 2005 Nov; 3():10. PubMed ID: 16281982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS.
    Stavem K; Frøland SS; Hellum KB
    Qual Life Res; 2005 May; 14(4):971-80. PubMed ID: 16041894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do Zimbabweans value health states?
    Jelsma J; Hansen K; De Weerdt W; De Cock P; Kind P
    Popul Health Metr; 2003 Dec; 1(1):11. PubMed ID: 14678566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource allocation, social values and the QALY: a review of the debate and empirical evidence.
    Schwappach DL
    Health Expect; 2002 Sep; 5(3):210-22. PubMed ID: 12199660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The equivalence of numbers: the social value of avoiding health decline: an experimental Web-based study.
    Schwappach DL
    BMC Med Inform Decis Mak; 2002; 2():3. PubMed ID: 11879529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life.
    Hawthorne G; Richardson J; Osborne R
    Qual Life Res; 1999 May; 8(3):209-24. PubMed ID: 10472152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From selfish individualism to citizenship: avoiding health economics' reputed 'dead end'.
    Wiseman V
    Health Care Anal; 1998 Jun; 6(2):113-22. PubMed ID: 10181502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuation of EuroQOL (EQ-5D) health states in an adult US sample.
    Johnson JA; Coons SJ; Ergo A; Szava-Kovats G
    Pharmacoeconomics; 1998 Apr; 13(4):421-33. PubMed ID: 10178666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.
    Evans KW; Boan JA; Evans JL; Shuaib A
    Pharmacoeconomics; 1997 Nov; 12(5):565-77. PubMed ID: 10174323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
    Nord E; Wisløff F; Hjorth M; Westin J
    Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys.
    Nord E; Richardson J; Macarounas-Kirchmann K
    Int J Technol Assess Health Care; 1993; 9(4):463-78. PubMed ID: 8288424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.